<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944799</url>
  </required_header>
  <id_info>
    <org_study_id>2015-003638-28</org_study_id>
    <nct_id>NCT02944799</nct_id>
  </id_info>
  <brief_title>Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis</brief_title>
  <acronym>ALOSTRA</acronym>
  <official_title>Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled trial including 160 consecutive patients who&#xD;
      have been diagnosed with both rheumatoid arthritis (RA) and low bone mass and have been&#xD;
      treated with alendronate (ALN) for five years or more. Patients will be randomized to&#xD;
      discontinuation or continuation of alendronate. Outcomes are measured using dual energy&#xD;
      absorptiometry (DXA), High Resolution peripheral Quantitative Computer Tomography (HR-pQCT)&#xD;
      and biochemical markers of bone metabolism and inflammation after 6 months, 1 and 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives:&#xD;
&#xD;
        -  to assess the effect of discontinuation of alendronate (ALN) on C-terminal telopeptide&#xD;
           crosslinks (CTX) and Type 1 procollagen amino-terminal-propeptide (P1NP) after 6 months&#xD;
&#xD;
        -  to assess the effect of discontinuation of ALN on bone mineral density (BMD) on DXA&#xD;
           scans at 2 years&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  to assess the effect of discontinuation of ALN on vBMD on HRpQCT scans at 2 years&#xD;
&#xD;
        -  to assess the effect of discontinuation of ALN on biochemical markers of bone metabolism&#xD;
           after 6 and 24 months&#xD;
&#xD;
        -  to evaluate and compare the changes in vBMD in cancellous and cortical bone&#xD;
           respectively, after discontinuation of ALN&#xD;
&#xD;
        -  to evaluate the correlation between RA activity measured by DAS28-CRP and bone&#xD;
           metabolism&#xD;
&#xD;
      Interventions:&#xD;
&#xD;
      Participants will be randomized to one of two groups:&#xD;
&#xD;
        -  Group 1 (Alendronate group, N=80): alendronate 70mg/weekly, calcium 800 mg/day and&#xD;
           vitamin D 38 µg/day&#xD;
&#xD;
        -  Group 2 (Placebo group, N=80): alendronate-placebo, calcium 800 mg/day and vitamin D 38&#xD;
           µg/day&#xD;
&#xD;
      Concomitant treatment of RA:&#xD;
&#xD;
      Patients included in this trial will be treated according to the national Danish guidelines&#xD;
      for treatment of RA&#xD;
&#xD;
      Assignment of intervention:&#xD;
&#xD;
      The Hospital Pharmacy in Aarhus will carry out the randomization. Using the web-based&#xD;
      programme randomization.com a list of distribution is produced. The randomization will be&#xD;
      stratified according to which type of treatment the patients receives for RA. All patients&#xD;
      receiving traditional DMARDs such as methotrexate, sulfasalazine, hydroxychloroquine,&#xD;
      leflunomide or a combination hereof will be allocated to grop A. All patients receiving any&#xD;
      kind of biological treatment (bDMARDs) e.g. infliximab will be allocated to group B. When&#xD;
      requesting randomization from the hospital pharmacy, the investigator will note if the&#xD;
      patient is group A or B. Both group A and B will undergo randomization 1:1 in the ALN and&#xD;
      placebo groups, using block randomization in blocks of 6.&#xD;
&#xD;
      Participant timeline:&#xD;
&#xD;
      Patients will be seen at a screening visit, at baseline and after 3, 6, 12, and 24 months&#xD;
&#xD;
      Procedures at screening: informed consent procedures, full medical history, full physical&#xD;
      examination, 12- lead EKG, screening blood samples, DXA scan&#xD;
&#xD;
      Procedures at all other visits: focused physical exam of joints and back, measurement of&#xD;
      blood pressure, pulse and temperature, calculation of DAS28-CRP and HAQ scores, screening for&#xD;
      adverse events, routine and project blood samples.&#xD;
&#xD;
      At baseline visit: HRpQCT scan and Xrays of hands and feet&#xD;
&#xD;
      At visit 12 months: DXA and HRpQCT scans&#xD;
&#xD;
      At visit 24 months: DXA and HRpQCT scans, xrays of hands and feet&#xD;
&#xD;
      Clinical laboratory tests:&#xD;
&#xD;
        -  routine analyses include: alkaline phosphatase, creatinine, alanine aminotransferase&#xD;
           (ALT), platelet count, Hemoglobin, white blood cells, absolute neutrophil count,&#xD;
           absolute lymphocyte count, CRP (total 8ml)&#xD;
&#xD;
        -  screening analyses: routine analysis as well as s-FSH and/or HCG (women only), calcium,&#xD;
           PTH, vitamin-D status, TSH (total 16 ml)&#xD;
&#xD;
        -  primary project analyses include: CTX and P1NP (total 4 ml)&#xD;
&#xD;
        -  secondary project analysis include: bone specific alkaline phosphatase, RANK-L,&#xD;
           sclerostin, tumor necrosis factor, osteoprotegrin, P1NP, osteocalcin, IL-6, IL-17 (total&#xD;
           8 ml)&#xD;
&#xD;
        -  extra blood bank sample - 3ml serum, 2 ml plasma and full blood for storage and later&#xD;
           analysis&#xD;
&#xD;
      DXA scan:&#xD;
&#xD;
      Study participants will be scanned using a Hologic discovery machine.To ensure comparative&#xD;
      results, the same machine will be used for each participant at each scan. Lumbar spine&#xD;
      anterior-posterior and left hip pictures are recorded following local guidelines.&#xD;
&#xD;
      HR-pQCT scan:&#xD;
&#xD;
      Bone structure will be measured at metacarpals 2-4 and proximal radius using the model XTREME&#xD;
      CT-I SCANCO MEDICAL AG; SCHWEIZ. A 2,7 cm long area over the right hand second and third&#xD;
      metacarpophalangeal joint is scanned. After this a 0,9 cm long part of the distal radius is&#xD;
      scanned The 3D dataset will be analyzed and number and volume of erosions calculated.&#xD;
      Volumetric BMD is calculated for both cortical and trabecular bone, trabecular number and&#xD;
      separation according to the built-in software.&#xD;
&#xD;
      X-rays of hands and feet:&#xD;
&#xD;
      Standardized X-rays of the hands/forearms and upper feet in separate AP (dorsopalmar)&#xD;
      projections of each hand and wrist and dorsoplantar projections of the feet Images of the&#xD;
      hands will be centered around the 2nd and 3rd MCPjoints The foot must not be tilted in the&#xD;
      case of suboptimal projections of the MTP-joints. All images will be scored centrally&#xD;
      according to the Sharp-van der Heide score system.&#xD;
&#xD;
      DAS28-CRP:&#xD;
&#xD;
      A clinical activity score for arthritis activity is calculated by means of&#xD;
&#xD;
        -  number of tender and swollen joint scores including the following twenty eight joints:&#xD;
           shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints&#xD;
           and the knees.&#xD;
&#xD;
        -  crp-measurement&#xD;
&#xD;
        -  general health assessment by the doctor using a VAS-scale A number between 0 and 10 is&#xD;
           calculated. Values &lt;2,6 are considered in remission, values &gt;2,6 are considered as&#xD;
           evidence of disease activity&#xD;
&#xD;
      Harms:&#xD;
&#xD;
      The dose of radiation is estimated to 0,07mSievert, as each HR-pQCT scan contributes with&#xD;
      0,012mS, each DXAscan 0,01mS and each Xray status of hands and feet 0,008mS. The average&#xD;
      annual background radiation exposure in Denmark is 3mSievert. Thus the participants will&#xD;
      receive an increased radiation dose corresponding to 9 days of background radiation.&#xD;
&#xD;
      The HR-pQCT-scans require fixation of the hand for 8 and 3 minutes respectively, which might&#xD;
      cause slight discomfort.&#xD;
&#xD;
      Safety measures:&#xD;
&#xD;
      All routine biochemical markers (visit 1-5) will be analyzed and evaluated promptly. An&#xD;
      increase in alkaline phosphatase of more than 100% will lead to the participant being called&#xD;
      in for an extra visit for further evaluation of the cause. The patient will be withdrawn from&#xD;
      the study if there is suspicion of accelerated bone loss.&#xD;
&#xD;
      All fractures will be recorded and in the case of low-energy fracture the patient will be&#xD;
      withdrawn from the study.&#xD;
&#xD;
      The 12 month DXA scans will be reviewed and a BMD decrease of more than 5% will lead to&#xD;
      exclusion from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>Change from baseline to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C-terminal telopeptide crosslinks (CTX)</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>serological marker of bone metabolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type 1 procollagen amino-terminal-propeptide (P1NP)</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>serological marker of bone metabolism</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continues treatment with alendronate, 70mgs oral tablet once every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, one every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Discontinuation of alendronate treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>Daily dietary supplement of 800mg calcium</description>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Daily dietary supplement of 38 micrograms vitamin D</description>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (&gt; 18 years) with rheumatoid arthritis according to the ACR(1987 or&#xD;
             2010)/EULAR (2010) classification criteria (12)&#xD;
&#xD;
          -  treated with alendronate for five years or more&#xD;
&#xD;
          -  current T-score on DXA better than or equal to -2,5 (femoral) and -3,0 (vertebral)&#xD;
&#xD;
          -  receiving treatment on an outpatient basis&#xD;
&#xD;
          -  negative pregnancy test (serum HCG) prior to trial start and the use of contraception&#xD;
             throughout the study period and for 1 month after conclusion of the study period for&#xD;
             women of childbearing potential. Plasma T1/2 of ALN is less than 2 hours. The forms of&#xD;
             contraception include: intrauterine device (IUD) and hormonal anticontraceptives&#xD;
             (contraceptive pill, implant, patch or injection or vaginal ring). Sterile and&#xD;
             non-fertile participants do not have to use contraception. Sterile or non-fertile is&#xD;
             defined as having undergone surgical sterilization (vasectomy / bilateral tubectomy,&#xD;
             hysterectomy and bilateral oophorectomy) or post-menopausal status, defined as absence&#xD;
             of menstrual period for at least 12 months prior to enrollment. Postmenopause will be&#xD;
             confirmed by measurement of s-FSH prior to enrollment.&#xD;
&#xD;
          -  ability and willingness to give written informed consent and to meet the requirements&#xD;
             of the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of hip fracture due to osteoporosis&#xD;
&#xD;
          -  history of vertebral fracture of more than one vertebrae or other fragility fractures&#xD;
             within the last three years (fingers and toes not included)&#xD;
&#xD;
          -  osteonecrosis of the jaw.&#xD;
&#xD;
          -  history of or ongoing systemic GC treatment within the last 6 months (intraarticular&#xD;
             injections are approved)&#xD;
&#xD;
          -  known allergy toward any components of the study medicine&#xD;
&#xD;
          -  prior or ongoing treatment with other antiosteoporosis drugs such as hormone&#xD;
             replacement therapy or teriparatide&#xD;
&#xD;
          -  active malignant disease&#xD;
&#xD;
          -  metabolic bone disease other than osteoporosis&#xD;
&#xD;
          -  hypo- or hyperthyroidism&#xD;
&#xD;
          -  hypocalcaemia&#xD;
&#xD;
          -  impaired renal function (eGFR &lt;35ml/min)&#xD;
&#xD;
          -  known disease of the esophagus that might impair the ability to swallow the tablets&#xD;
             such as achalasia, dysphagia or strictures&#xD;
&#xD;
          -  history of upper gastrointestinal disease within 1 year prior to enrollment such as&#xD;
             peptic ulcer, upper GI bleeding, gastritis, duodenitis or surgical procedures to the&#xD;
             upper GI-tract&#xD;
&#xD;
          -  allergy towards any of the substances in the study medicine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hauge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silkeborg Regional Hospital</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

